ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1196

Inflammation Develops in a Toll-like Receptor 9-Independent Manner in Experimental Arthritis and Rheumatoid Arthritis

Julie Mussard1, Matthieu Ribon1, Gaelle Clavel2, Marie-Christophe Boissier3 and Patrice Decker1, 1INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, 2Fondation Ophtalmologique A. De Rothschild, Paris cedex 19, France, 3INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: animal models and toll-like receptors, innate immunity, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Signaling Mechanisms

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis (RA) is an inflammatory disease of unknown etiology. Toll-like receptor (TLR) 9 recognizes pathogen-derived DNA and even self DNA under certain circumstances. Interestingly, environmental factors and especially bacterial infections have been suggested to favor RA development. In addition, TLR9 might also recognize damage-associated molecular patterns (DAMP) in RA. Since the involvement of TLR9 in RA remains unclear, we have investigated whether TLR9 is necessary for disease development in a mouse model of RA and we have analyzed TLR9 expression in samples from patients and controls.

Methods

Disease development was followed in the collagen-induced arthritis (CIA) mouse model. The impact of TLR9 was evaluated by comparing wild-type (WT) mice and TLR9-knockout (KO) true littermates. Arthritis was followed by clinical score evaluation. Inflammation and bone destruction were estimated by histology. Anti-collagen antibody, C3a and blood cytokine levels were measured by ELISA and Luminex. B and T lymphocytes as well as neutrophils were analyzed by flow cytometry. Osteoclastogenesis was analyzed by culturing bone marrow cells with M-CSF and RANKL and then counting TRAP-positive multinucleated cells by microscopy. Moreover, TLR9 expression was analyzed ex vivo by flow cytometry on whole blood from healthy donors and RA patients.

Results

We clearly show for the first time that TLR9 is not crucial in inflammatory arthritis. Indeed, TLR9 is not required for arthritis development in CIA as TLR9-KO mice strongly developed clinical arthritis. Accordingly, WT and KO mice produced similar levels of anti-collagen antibodies. As a control, we verified that WT and KO mice responded to complete Freund’s adjuvant. Moreover, inflammation and joint destruction were observed in both WT and TLR9-KO mice and at a similar level. In agreement with those observations, no statistically significant difference was noted between WT and KO mice regarding the percentage or the activation of lymphocytes and neutrophils in the blood, spleen and lymph nodes. Osteoclastogenesis and complement activation (the latter being estimated by C3a production) are similar in WT and TLR9-KO CIA mice. Importantly, TLR7 does not compensate TLR9 deficiency in vivo as there is no TLR7 over-expression in TLR9-deficeint mice. The impact of TLR9 on cytokine secretion in vivo is currently being analyzed. In human samples, we have shown that leukocytes from healthy donors and RA patients express endosomal and cell surface TLR9 at the same extent and accordingly TLR9 expression is not correlated with disease activity in patients.

Conclusion

This is the first demonstration that TLR9-KO mice clearly develop arthritis. Immune cells from RA patients do not over-express TLR9 in comparison to healthy donors. Our results thus suggest that TLR9 does not play a crucial role in inflammatory arthritis development in the CIA model and that there is no intrinsic abnormal TLR9 expression in RA patients. This also suggests that TLR9 is not strongly involved in the recognition of DAMP in RA.


Disclosure:

J. Mussard,
None;

M. Ribon,
None;

G. Clavel,
None;

M. C. Boissier,
None;

P. Decker,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammation-develops-in-a-toll-like-receptor-9-independent-manner-in-experimental-arthritis-and-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology